293 related articles for article (PubMed ID: 17242145)
1. Miltefosine affects lipid metabolism in Leishmania donovani promastigotes.
Rakotomanga M; Blanc S; Gaudin K; Chaminade P; Loiseau PM
Antimicrob Agents Chemother; 2007 Apr; 51(4):1425-30. PubMed ID: 17242145
[TBL] [Abstract][Full Text] [Related]
2. Alteration of fatty acid and sterol metabolism in miltefosine-resistant Leishmania donovani promastigotes and consequences for drug-membrane interactions.
Rakotomanga M; Saint-Pierre-Chazalet M; Loiseau PM
Antimicrob Agents Chemother; 2005 Jul; 49(7):2677-86. PubMed ID: 15980336
[TBL] [Abstract][Full Text] [Related]
3. Membrane sterol depletion impairs miltefosine action in wild-type and miltefosine-resistant Leishmania donovani promastigotes.
Saint-Pierre-Chazalet M; Ben Brahim M; Le Moyec L; Bories C; Rakotomanga M; Loiseau PM
J Antimicrob Chemother; 2009 Nov; 64(5):993-1001. PubMed ID: 19749205
[TBL] [Abstract][Full Text] [Related]
4. Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug.
Pérez-Victoria FJ; Castanys S; Gamarro F
Antimicrob Agents Chemother; 2003 Aug; 47(8):2397-403. PubMed ID: 12878496
[TBL] [Abstract][Full Text] [Related]
5. Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine).
Seifert K; Matu S; Javier Pérez-Victoria F; Castanys S; Gamarro F; Croft SL
Int J Antimicrob Agents; 2003 Oct; 22(4):380-7. PubMed ID: 14522101
[TBL] [Abstract][Full Text] [Related]
6. Miltefosine (hexadecylphosphocholine) inhibits cytochrome c oxidase in Leishmania donovani promastigotes.
Luque-Ortega JR; Rivas L
Antimicrob Agents Chemother; 2007 Apr; 51(4):1327-32. PubMed ID: 17283192
[TBL] [Abstract][Full Text] [Related]
7. Interaction between miltefosine and amphotericin B: consequences for their activities towards intestinal epithelial cells and Leishmania donovani promastigotes in vitro.
Ménez C; Buyse M; Besnard M; Farinotti R; Loiseau PM; Barratt G
Antimicrob Agents Chemother; 2006 Nov; 50(11):3793-800. PubMed ID: 16966395
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo.
Seifert K; Pérez-Victoria FJ; Stettler M; Sánchez-Cañete MP; Castanys S; Gamarro F; Croft SL
Int J Antimicrob Agents; 2007 Sep; 30(3):229-35. PubMed ID: 17628445
[TBL] [Abstract][Full Text] [Related]
9. A mitochondrial HSP70 (HSPA9B) is linked to miltefosine resistance and stress response in Leishmania donovani.
Vacchina P; Norris-Mullins B; Carlson ES; Morales MA
Parasit Vectors; 2016 Dec; 9(1):621. PubMed ID: 27906059
[TBL] [Abstract][Full Text] [Related]
10. Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes.
Paris C; Loiseau PM; Bories C; Bréard J
Antimicrob Agents Chemother; 2004 Mar; 48(3):852-9. PubMed ID: 14982775
[TBL] [Abstract][Full Text] [Related]
11. Miltefosine induces apoptosis in arsenite-resistant Leishmania donovani promastigotes through mitochondrial dysfunction.
Verma NK; Singh G; Dey CS
Exp Parasitol; 2007 May; 116(1):1-13. PubMed ID: 17161839
[TBL] [Abstract][Full Text] [Related]
12. Defeating Leishmania resistance to miltefosine (hexadecylphosphocholine) by peptide-mediated drug smuggling: a proof of mechanism for trypanosomatid chemotherapy.
Luque-Ortega JR; de la Torre BG; Hornillos V; Bart JM; Rueda C; Navarro M; Amat-Guerri F; Acuña AU; Andreu D; Rivas L
J Control Release; 2012 Aug; 161(3):835-42. PubMed ID: 22609351
[TBL] [Abstract][Full Text] [Related]
13. Antileishmanial and trypanocidal activities of new miltefosine liposomal formulations.
Papagiannaros A; Bories C; Demetzos C; Loiseau PM
Biomed Pharmacother; 2005 Dec; 59(10):545-50. PubMed ID: 16325367
[TBL] [Abstract][Full Text] [Related]
14. Short report: fluorescent Leishmania: application to anti-leishmanial drug testing.
Singh N; Dube A
Am J Trop Med Hyg; 2004 Oct; 71(4):400-2. PubMed ID: 15516633
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo antileishmanial efficacy of a new nitrilquinoline against Leishmania donovani.
Nakayama H; Desrivot J; Bories C; Franck X; Figadère B; Hocquemiller R; Fournet A; Loiseau PM
Biomed Pharmacother; 2007; 61(2-3):186-8. PubMed ID: 17360145
[TBL] [Abstract][Full Text] [Related]
16. Hexadecylphosphocholine (Miltefosine) stabilized chitosan modified Ampholipospheres as prototype co-delivery vehicle for enhanced killing of L. donovani.
Tripathi P; Jaiswal AK; Dube A; Mishra PR
Int J Biol Macromol; 2017 Dec; 105(Pt 1):625-637. PubMed ID: 28716750
[TBL] [Abstract][Full Text] [Related]
17. Leishmanicidal activity of edelfosine, miltefosine and ilmofosine.
Azzouz S; Maache M; Garcia RG; Osuna A
Basic Clin Pharmacol Toxicol; 2005 Jan; 96(1):60-5. PubMed ID: 15667597
[TBL] [Abstract][Full Text] [Related]
18. Genomic Appraisal of the Multifactorial Basis for In Vitro Acquisition of Miltefosine Resistance in Leishmania donovani.
Vacchina P; Norris-Mullins B; Abengózar MA; Viamontes CG; Sarro J; Stephens MT; Pfrender ME; Rivas L; Morales MA
Antimicrob Agents Chemother; 2016 Jul; 60(7):4089-100. PubMed ID: 27114280
[TBL] [Abstract][Full Text] [Related]
19. In vitro selection of miltefosine resistance in promastigotes of Leishmania donovani from Nepal: genomic and metabolomic characterization.
Shaw CD; Lonchamp J; Downing T; Imamura H; Freeman TM; Cotton JA; Sanders M; Blackburn G; Dujardin JC; Rijal S; Khanal B; Illingworth CJ; Coombs GH; Carter KC
Mol Microbiol; 2016 Mar; 99(6):1134-48. PubMed ID: 26713880
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo interactions between miltefosine and other antileishmanial drugs.
Seifert K; Croft SL
Antimicrob Agents Chemother; 2006 Jan; 50(1):73-9. PubMed ID: 16377670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]